Obesity-driven HFpEF: the 2026 review

This article is for educational purposes only and does not constitute medical advice. Heart failure is a serious medical condition. If you have symptoms of heart failure or a cardiovascular diagnosis, consult a cardiologist or qualified healthcare provider before making any decisions about treatment.

Heart failure with preserved ejection fraction, abbreviated HFpEF, is now the most common form of heart failure in high-income countries. Unlike classic heart failure, where the heart's pumping function is impaired, HFpEF is a condition in which the heart contracts normally but fails to relax and fill properly between beats. Fluid backs up, breathlessness increases on exertion, and quality of life deteriorates. Lead SUMMIT trial investigator Milton Packer has stated that obesity has become the dominant driver of this phenotype^[1].

A 2026 systematic review in Current Problems in Cardiology set out to map the full chain from obesity pathobiology to clinical prescribing in HFpEF, and to propose a practical therapeutic framework for clinicians^[2]. This article summarises what that review found, why the SUMMIT trial matters, and what the evidence means for patients with obesity-related HFpEF.

How obesity drives HFpEF: the pathobiology chain

Obesity does not simply add mechanical load to the heart. The connection between excess adiposity and HFpEF runs through several distinct biological pathways that the 2026 review outlines systematically^[2].

First, visceral adiposity drives chronic low-grade inflammation. Enlarged adipocytes release pro-inflammatory cytokines including interleukin-6 and tumour necrosis factor-alpha. These cytokines promote systemic inflammation and, over time, reach the myocardium, causing myocardial injury and fibrosis.

Second, obesity promotes sodium retention and plasma volume expansion. An expanded circulating volume raises cardiac filling pressures. When the left ventricle wall has stiffened from adipose-driven fibrosis, it cannot accommodate that extra volume without pressure rising sharply, which is the hemodynamic signature of HFpEF.

Third, metabolic dysfunction compounds the picture. Insulin resistance, common in obesity, impairs the heart's ability to use energy substrates efficiently. The myocardium in HFpEF increasingly shifts toward fatty acid oxidation, which is less oxygen-efficient and contributes to diastolic dysfunction.

The 2026 review synthesises these mechanisms into a framework where obesity is not merely a risk factor but the central pathobiological driver in a large subset of HFpEF patients, making weight-focused therapies a mechanistically rational treatment target^[2].

The SUMMIT trial: what the data show

The SUMMIT trial, published in the New England Journal of Medicine in 2025, enrolled 731 adults with HFpEF and obesity (mean BMI 38 kg/m2) and randomised them to tirzepatide or placebo over a median follow-up of approximately two years^[1]. Tirzepatide is a dual GIP and GLP-1 receptor agonist approved as Mounjaro (type-2 diabetes) and Zepbound (weight management and obstructive sleep apnoea).

The primary endpoint was a composite of cardiovascular death or worsening heart failure events. The tirzepatide arm reached this endpoint in 9.9% of participants versus 15.3% in the placebo arm, a hazard ratio of 0.62 (95% CI 0.41 to 0.95, P=0.026), representing approximately a 38% relative risk reduction^[1].

Secondary outcomes reinforced the primary result. Heart failure hospitalisation rates were 3.3% with tirzepatide versus 7.1% with placebo (HR 0.44). Patients in the tirzepatide group gained 6.9 points on the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 52 weeks, a validated measure of heart failure symptom burden. Six-minute walk distance improved by 18 metres more than in the placebo group. Systemic inflammation, measured by high-sensitivity CRP, fell by 38.8% with tirzepatide versus 5.9% with placebo^[1].

Mean body weight fell by 13.9% with tirzepatide versus 2.2% with placebo. Less visceral adiposity means reduced inflammatory signalling, lower plasma volume, and less pressure on a stiff ventricle.

Linking the trial findings to the pathobiology

The 2026 systematic review positions SUMMIT as the first trial to demonstrate hard clinical event benefit in HFpEF by targeting obesity-driven pathobiology directly^[2]. Earlier trials with conventional heart failure drugs mostly failed to show benefit in HFpEF because they addressed hemodynamics without addressing adipose-driven inflammation and metabolic dysfunction.

GLP-1 and GIP receptor agonists act on multiple points in the pathobiology chain. Beyond weight reduction, GLP-1 receptors are expressed in cardiac tissue and may have direct anti-inflammatory and anti-fibrotic effects. The pronounced CRP reduction in SUMMIT (nearly 33 percentage points more than placebo) is consistent with a drug acting on systemic inflammation, not body weight alone^[1].

What the 2026 review recommends for clinicians

The systematic review proposes a tiered therapeutic framework for obesity-driven HFpEF^[2]. It recommends that clinicians first confirm the obesity-HFpEF phenotype: elevated BMI, diastolic dysfunction on imaging, elevated filling pressures, and signs of systemic inflammation. Once confirmed, the review suggests that weight-reducing therapies with demonstrated HFpEF benefit, specifically GLP-1/GIP receptor agonists, be considered alongside standard care such as diuretics for congestion.

The review notes that tirzepatide is not approved specifically for HFpEF in any jurisdiction as of the time of writing. SUMMIT's data support its use in this population, but prescribing for the HFpEF indication is off-label^[3]. Many HFpEF patients qualify under the approved obesity or type-2 diabetes indications that overlap considerably with the SUMMIT population.

The authors flag practical prescribing considerations: tirzepatide is uptitrated slowly (the trial started at 2.5 mg per week, escalating toward 15 mg per week), gastrointestinal side effects are the main early tolerability issue, and 4.1% of SUMMIT participants discontinued due to GI symptoms^[1]. Patients with advanced heart failure or severe renal impairment require individualised assessment.

What remains uncertain

SUMMIT enrolled a specific population with obesity-driven HFpEF; it is not known whether benefits extend to leaner patients or those without the inflammatory phenotype. The optimal treatment duration is also unestablished, and patients who discontinue tirzepatide regain weight and likely experience symptom recurrence.

The 2026 review notes that SUMMIT did not include a head-to-head comparison with semaglutide in HFpEF. Data on longer-term cardiovascular mortality remain limited: the numerically higher cardiovascular death rate in the tirzepatide arm (2.2% vs 1.4%) did not reach statistical significance, and Packer attributed it to chance given the small event numbers^[1].

What this means for patients

For people living with both obesity and HFpEF, SUMMIT provides the most direct trial evidence to date that a weight-focused medical therapy can reduce the rate of hospitalisation and improve day-to-day symptoms. The 6.9-point gain in the KCCQ score is clinically meaningful: it corresponds roughly to moving from a poor to a fair health status category on that instrument^[1].

Tirzepatide is a prescription medicine. It is not appropriate to source or self-prescribe it for HFpEF. A cardiologist familiar with heart failure management should be involved in any prescribing decision. For background on tirzepatide's mechanisms, approved indications, and regulatory status across jurisdictions, see the tirzepatide overview.